Vetter to build $320M plant in U.S.


When word got out last week that German CDMO Vetter would build a sterile injectables manufacturing facility in the Chicago area, details were thin. But now the company has filled them in, saying it will invest $320 million and hopes to eventually have 400 to 500 workers at the site.

Vetter is seeking approval from local authorities for permission to build out a 1.1-million-square-foot facility over a decade on an 18-acre site in Des Plaines, IL. The site used to be home to the Salvation Army’s central territory headquarters.

The facility would handle fill and finish of aseptically prefilled syringe systems, cartridges and vials and is expected to initially provide about 300 jobs, but Vetter is hoping to expand it over time. The Ravensburg, Germany-based company already has a small clinical supply facility in the nearby Village of Skokie where about 70 people work, but Vetter said it wanted to be able to offer its clients commercial manufacturing capabilities in the U.S.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

“Several of our customers have requested commercial manufacturing resources both in U.S. and Europe for their multifaceted market production needs,” Vetter Managing Director Peter Soelkner said in a statement.

Vetter has been expanding for several years and in 2013 announced plans to invest about $100 million in its facilities in Ravensburg and in Skokie.  

- here’s the release 

Related Articles: 
New Chicago-area plant for Germany's Vetter promises 300 jobs 
Vetter putting $100M into its production network

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

Pfizer is pushing back on a Thursday report claiming it suddenly revised its COVID-19 vaccine targets for 2020, saying it announced that last month.